Credit Suisse’s Altimmune ALT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
$455K Buy
+44,599
New +$454K ﹤0.01% 2675
2023
Q2
Sell
-41,372
Closed -$175K 3164
2023
Q1
$175K Buy
41,372
+3,235
+8% +$38.4K ﹤0.01% 3143
2022
Q4
$627K Buy
+38,137
New +$428K ﹤0.01% 2638
2022
Q3
Sell
-21
Closed 4023
2022
Q2
$0 Buy
+21
New +$130 ﹤0.01% 3897
2021
Q4
Sell
-1,410,397
Closed -$16M 4481
2021
Q3
$16M Sell
1,410,397
-19,378
-1% -$236K 0.01% 1213
2021
Q2
$14.1M Buy
1,429,775
+515,336
+56% +$7.05M 0.01% 1351
2021
Q1
$12.9M Sell
914,439
-279,280
-23% -$4.52M 0.01% 1416
2020
Q4
$13.5M Buy
+1,193,719
New +$14.1M 0.01% 1398
2017
Q3
Sell
-449
Closed -$43K 4168
2017
Q2
$43K Buy
+449
New +$74.6K ﹤0.01% 3786
2017
Q1
Sell
-263
Closed -$256K 3796
2016
Q4
$256K Buy
263
+184
+233% +$165K ﹤0.01% 3721
2016
Q3
$68K Sell
79
-10
-11% -$7.84K ﹤0.01% 3981
2016
Q2
$65K Buy
+89
New +$60.9K ﹤0.01% 4123
2015
Q2
Sell
-85
Closed -$42K 4512
2015
Q1
$42K Buy
+85
New +$42.4K ﹤0.01% 4290

Other funds holding ALT

Credit Suisse's ALT Position: Q1 2024 in Review

Credit Suisse opened a new position in Altimmune (ALT) in Q1 2024: 44,599 shares worth $455K. The stake represents ﹤0.01% of the portfolio and ranks #2675 among its holdings. This is a return to the name: Credit Suisse previously reported a position in ALT as recently as Q1 2023.

Credit Suisse first reported a position in ALT in Q1 2015 and has held it in 13 quarters since. The position peaked at $16M in Q3 2021. 172 funds tracked by Wall St. Rank hold ALT as of Q1 2024.

  • Credit Suisse held 44,599 shares of Altimmune worth $455K as of Q1 2024.
  • Altimmune was a new Credit Suisse position in Q1 2024.
  • Altimmune made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2675 holding.
  • Credit Suisse first reported a position in Altimmune in Q1 2015 and has held it in 13 quarters since.
  • Credit Suisse's Altimmune position peaked at $16M in Q3 2021.
  • 172 funds tracked by Wall St. Rank held Altimmune as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.